APA (7th ed.) Citation

Nagai, H., Saito, M., Adachi, E., Sakai-Tagawa, Y., Yamayoshi, S., Kiso, M., . . . Yotsuyanagi, H. (2022). Casirivimab/Imdevimab for Active COVID-19 Pneumonia Which Persisted for Nine Months in a Patient with Follicular Lymphoma during Anti-CD20 Therapy. Japanese Journal of Infectious Diseases, 75(6), 608-611. https://doi.org/10.7883/yoken.JJID.2022.092

Chicago Style (17th ed.) Citation

Nagai, Hiroyuki, et al. "Casirivimab/Imdevimab for Active COVID-19 Pneumonia Which Persisted for Nine Months in a Patient with Follicular Lymphoma During Anti-CD20 Therapy." Japanese Journal of Infectious Diseases 75, no. 6 (2022): 608-611. https://doi.org/10.7883/yoken.JJID.2022.092.

MLA (9th ed.) Citation

Nagai, Hiroyuki, et al. "Casirivimab/Imdevimab for Active COVID-19 Pneumonia Which Persisted for Nine Months in a Patient with Follicular Lymphoma During Anti-CD20 Therapy." Japanese Journal of Infectious Diseases, vol. 75, no. 6, 2022, pp. 608-611, https://doi.org/10.7883/yoken.JJID.2022.092.